Follicular Lymphoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Follicular Lymphoma – Pipeline Review, H2 2016’, provides an overview of the Follicular Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Follicular Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma

The report reviews pipeline therapeutics for Follicular Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Follicular Lymphoma therapeutics and enlists all their major and minor projects

The report assesses Follicular Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Follicular Lymphoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Affimed GmbH

Amgen Inc

Asana BioSciences LLC

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

Biocon Ltd

Biogen Inc

Biogenomics Limited

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

Celldex Therapeutics Inc

Celltrion Inc

Cellular Biomedicine Group Inc

Coherus BioSciences Inc

Constellation Pharmaceuticals Inc

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp

Curis Inc

Dynavax Technologies Corp

Eisai Co Ltd

EpiZyme Inc

F. Hoffmann-La Roche Ltd

Genentech Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Hutchison MediPharma Ltd

Immune Design Corp

ImmunoGen Inc

Immunomedics Inc

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

MedImmune LLC

Medivation Inc

MEI Pharma Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

MorphoSys AG

Nordic Nanovector ASA

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharmacyclics Inc

Portola Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

Sandoz International GmbH

Seattle Genetics Inc

Takeda Pharmaceutical Company Ltd

TG Therapeutics Inc

Verastem Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Follicular Lymphoma Overview 7

Therapeutics Development 8

Follicular Lymphoma - Therapeutics under Development by Companies 10

Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 15

Follicular Lymphoma - Pipeline Products Glance 16

Follicular Lymphoma - Products under Development by Companies 19

Follicular Lymphoma - Products under Investigation by Universities/Institutes 25

Follicular Lymphoma - Companies Involved in Therapeutics Development 26

Follicular Lymphoma - Therapeutics Assessment 83

Drug Profiles 97

Follicular Lymphoma - Dormant Projects 507

Follicular Lymphoma - Discontinued Products 510

Follicular Lymphoma - Product Development Milestones 511

Appendix 528

List of Tables

List of Tables

Number of Products under Development for Follicular Lymphoma, H2 2016 19

Number of Products under Development for Follicular Lymphoma – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 22

Number of Products under Development by Companies, H2 2016 (Contd..1) 23

Number of Products under Development by Companies, H2 2016 (Contd..2) 24

Number of Products under Development by Companies, H2 2016 (Contd..3) 25

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Development, H2 2016 29

Products under Development by Companies, H2 2016 30

Products under Development by Companies, H2 2016 (Contd..1) 31

Products under Development by Companies, H2 2016 (Contd..2) 32

Products under Development by Companies, H2 2016 (Contd..3) 33

Products under Development by Companies, H2 2016 (Contd..4) 34

Products under Development by Companies, H2 2016 (Contd..5) 35

Products under Investigation by Universities/Institutes, H2 2016 36

Follicular Lymphoma – Pipeline by AbbVie Inc, H2 2016 37

Follicular Lymphoma – Pipeline by Affimed GmbH, H2 2016 38

Follicular Lymphoma – Pipeline by Amgen Inc, H2 2016 39

Follicular Lymphoma – Pipeline by Asana BioSciences LLC, H2 2016 40

Follicular Lymphoma – Pipeline by Bayer AG, H2 2016 41

Follicular Lymphoma – Pipeline by BeiGene Ltd, H2 2016 42

Follicular Lymphoma – Pipeline by Bio-Path Holdings Inc, H2 2016 43

Follicular Lymphoma – Pipeline by Biocon Ltd, H2 2016 44

Follicular Lymphoma – Pipeline by Biogen Inc, H2 2016 45

Follicular Lymphoma – Pipeline by Biogenomics Limited, H2 2016 46

Follicular Lymphoma – Pipeline by Biothera Pharmaceutical Inc, H2 2016 47

Follicular Lymphoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 48

Follicular Lymphoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 49

Follicular Lymphoma – Pipeline by Celgene Corp, H2 2016 50

Follicular Lymphoma – Pipeline by Celldex Therapeutics Inc, H2 2016 51

Follicular Lymphoma – Pipeline by Celltrion Inc, H2 2016 52

Follicular Lymphoma – Pipeline by Cellular Biomedicine Group Inc, H2 2016 53

Follicular Lymphoma – Pipeline by Coherus BioSciences Inc, H2 2016 54

Follicular Lymphoma – Pipeline by Constellation Pharmaceuticals Inc, H2 2016 55

Follicular Lymphoma – Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 56

Follicular Lymphoma – Pipeline by CTI BioPharma Corp, H2 2016 57

Follicular Lymphoma – Pipeline by Curis Inc, H2 2016 58

Follicular Lymphoma – Pipeline by Dynavax Technologies Corp, H2 2016 59

Follicular Lymphoma – Pipeline by Eisai Co Ltd, H2 2016 60

Follicular Lymphoma – Pipeline by EpiZyme Inc, H2 2016 61

Follicular Lymphoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 62

Follicular Lymphoma – Pipeline by Genentech Inc, H2 2016 63

Follicular Lymphoma – Pipeline by Gilead Sciences Inc, H2 2016 64

Follicular Lymphoma – Pipeline by GlaxoSmithKline Plc, H2 2016 65

Follicular Lymphoma – Pipeline by Hutchison MediPharma Ltd, H2 2016 66

Follicular Lymphoma – Pipeline by Immune Design Corp, H2 2016 67

Follicular Lymphoma – Pipeline by ImmunoGen Inc, H2 2016 68

Follicular Lymphoma – Pipeline by Immunomedics Inc, H2 2016 69

Follicular Lymphoma – Pipeline by Johnson & Johnson, H2 2016 70

Follicular Lymphoma – Pipeline by Juno Therapeutics Inc, H2 2016 71

Follicular Lymphoma – Pipeline by Karyopharm Therapeutics Inc, H2 2016 72

Follicular Lymphoma – Pipeline by Kite Pharma Inc, H2 2016 73

Follicular Lymphoma – Pipeline by MedImmune LLC, H2 2016 74

Follicular Lymphoma – Pipeline by Medivation Inc, H2 2016 75

Follicular Lymphoma – Pipeline by MEI Pharma Inc, H2 2016 76

Follicular Lymphoma – Pipeline by Merck & Co Inc, H2 2016 77

Follicular Lymphoma – Pipeline by Merck KGaA, H2 2016 78

Follicular Lymphoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 79

Follicular Lymphoma – Pipeline by Mirati Therapeutics Inc, H2 2016 80

Follicular Lymphoma – Pipeline by MorphoSys AG, H2 2016 81

Follicular Lymphoma – Pipeline by Nordic Nanovector ASA, H2 2016 82

Follicular Lymphoma – Pipeline by Novartis AG, H2 2016 83

Follicular Lymphoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 84

Follicular Lymphoma – Pipeline by Pfizer Inc, H2 2016 85

Follicular Lymphoma – Pipeline by Pharmacyclics Inc, H2 2016 86

Follicular Lymphoma – Pipeline by Portola Pharmaceuticals Inc, H2 2016 87

Follicular Lymphoma – Pipeline by Rhizen Pharmaceuticals SA, H2 2016 88

Follicular Lymphoma – Pipeline by Sandoz International GmbH, H2 2016 89

Follicular Lymphoma – Pipeline by Seattle Genetics Inc, H2 2016 90

Follicular Lymphoma – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 91

Follicular Lymphoma – Pipeline by TG Therapeutics Inc, H2 2016 92

Follicular Lymphoma – Pipeline by Verastem Inc, H2 2016 93

Assessment by Monotherapy Products, H2 2016 94

Assessment by Combination Products, H2 2016 95

Number of Products by Stage and Target, H2 2016 97

Number of Products by Stage and Mechanism of Action, H2 2016 101

Number of Products by Stage and Route of Administration, H2 2016 105

Number of Products by Stage and Molecule Type, H2 2016 107

Follicular Lymphoma – Dormant Projects, H2 2016 518

Follicular Lymphoma – Dormant Projects (Contd..1), H2 2016 519

Follicular Lymphoma – Dormant Projects (Contd..2), H2 2016 520

Follicular Lymphoma – Discontinued Products, H2 2016 521

List of Figures

List of Figures

Number of Products under Development for Follicular Lymphoma, H2 2016 19

Number of Products under Development for Follicular Lymphoma – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Products, H2 2016 29

Assessment by Monotherapy Products, H2 2016 94

Number of Products by Top 10 Targets, H2 2016 96

Number of Products by Stage and Top 10 Targets, H2 2016 96

Number of Products by Top 10 Mechanism of Actions, H2 2016 100

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 100

Number of Products by Routes of Administration, H2 2016 104

Number of Products by Stage and Routes of Administration, H2 2016 104

Number of Products by Top 10 Molecule Types, H2 2016 106

Number of Products by Stage and Top 10 Molecule Types, H2 2016 106

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports